Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

The Telegraph highlighted a series of benefit fraud cases where claimants exaggerated illnesses to acquire vehicles from the ...

SO WHAT: If you purchased Tungray Technologies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law ...